Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT027 in Pleural Malignant Tumors
NCT06726564Phase 1Recruiting
- Sponsor
- Suzhou Maximum Bio-tech
- Start
- May 2024
- Primary completion
- May 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MT027 CAR-T cells in malignant pleural effusion (MPE), pleural neoplasm, pleural mesothelioma and 1 more, sponsored by Suzhou Maximum Bio-tech. Primary endpoints: Adverse Events at 1 year, Dose Limiting Toxicity at 28 days and 3 more. Started May 2024; status: recruiting.
02
Drugs
MT027 CAR-T cells
03
Conditions
malignant pleural effusion (MPE)pleural neoplasmpleural mesotheliomaPleural metastasis
Beyond the preview
Go deeper on NCT06726564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06726564.